Li Y - Search Results

1

Significance and Mechanisms of P-glycoprotein in Central Nervous System Diseases.

Huang L, Li B, Li X, Liu G, Liu R, Guo J, Xu B, Li Y, Fang W. Huang L, et al. Among authors: li y, li x, li b. Curr Drug Targets. 2019;20(11):1141-1155. doi: 10.2174/1389450120666190308144448. Curr Drug Targets. 2019. PMID: 30854958 Review.

2

Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.

Fang W, Li Y, Cai Y, Kang K, Yan F, Liu G, Huang W. Fang W, et al. Among authors: li y. J Pharm Pharmacol. 2007 Dec;59(12):1649-55. doi: 10.1211/jpp.59.12.0006. J Pharm Pharmacol. 2007. PMID: 18053326

3

Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 Isomers, tetrataisohydroquinolin derivatives.

Yan F, Jiang Y, Li YM, Zhen X, Cen J, Fang WR. Yan F, et al. Among authors: li ym. Biol Pharm Bull. 2008 Jun;31(6):1258-64. doi: 10.1248/bpb.31.1258. Biol Pharm Bull. 2008. PMID: 18520065 Free article.

4

Blood-brain barrier breakdown by PAF and protection by XQ-1H due to antagonism of PAF effects.

Deng Y, Fang W, Li Y, Cen J, Fang F, Lv P, Gong S, Mao L. Deng Y, et al. Among authors: li y. Eur J Pharmacol. 2009 Aug 15;616(1-3):43-7. doi: 10.1016/j.ejphar.2009.06.017. Epub 2009 Jun 23. Eur J Pharmacol. 2009. PMID: 19555682

5

Blood brain barrier permeability and therapeutic time window of Ginkgolide B in ischemia-reperfusion injury.

Fang W, Deng Y, Li Y, Shang E, Fang F, Lv P, Bai L, Qi Y, Yan F, Mao L. Fang W, et al. Among authors: li y. Eur J Pharm Sci. 2010 Jan 31;39(1-3):8-14. doi: 10.1016/j.ejps.2009.10.002. Epub 2009 Oct 13. Eur J Pharm Sci. 2010. PMID: 19833202

6

Effect and mechanism of AR-6 in experimental rheumatoid arthritis.

Sun SX, Li YM, Fang WR, Cheng P, Liu L, Li F. Sun SX, et al. Clin Exp Med. 2010 Jun;10(2):113-21. doi: 10.1007/s10238-009-0075-8. Epub 2009 Oct 20. Clin Exp Med. 2010. PMID: 19842015

7

Immunomodulatory activity of a Chinese herbal drug Yi Shen Juan Bi in adjuvant arthritis.

Perera PK, Li Y, Peng C, Fang W, Han C. Perera PK, et al. Among authors: li y. Indian J Pharmacol. 2010 Apr;42(2):65-9. doi: 10.4103/0253-7613.64489. Indian J Pharmacol. 2010. PMID: 20711367 Free PMC article.

8

HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM.

Cen J, Qi Y, Tao YF, Deng Y, Fang WR, Li YM, Zhang LY, Huang WL. Cen J, et al. Among authors: li ym. Eur J Pharmacol. 2010 Nov 25;647(1-3):21-30. doi: 10.1016/j.ejphar.2010.08.013. Epub 2010 Sep 9. Eur J Pharmacol. 2010. PMID: 20816813

9

Platelet activating factor induces blood brain barrier permeability alteration in vitro.

Fang W, Geng X, Deng Y, Li Y, Shang E, Cen J, Lv P. Fang W, et al. Among authors: li y. J Neuroimmunol. 2011 Jan;230(1-2):42-7. doi: 10.1016/j.jneuroim.2010.08.015. Epub 2010 Sep 25. J Neuroimmunol. 2011. PMID: 20870297

10

Therapeutic time window for treatment of focal cerebral ischemia reperfusion injury with XQ-1h in rats.

Sun J, Li Y, Fang W, Mao L. Sun J, et al. Among authors: li y. Eur J Pharmacol. 2011 Sep;666(1-3):105-10. doi: 10.1016/j.ejphar.2011.05.048. Epub 2011 Jun 1. Eur J Pharmacol. 2011. PMID: 21645512

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

239,252 results

Search Page

Filters